Novogen Ltd. (NASDAQ:NVGN) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.

Zacks has also assigned Novogen an industry rank of 94 out of 265 based on the ratings given to its competitors.

Shares of Novogen (NASDAQ:NVGN) traded up 2.60% during mid-day trading on Tuesday, reaching $1.97. The company had a trading volume of 17,336 shares. The firm has a 50 day moving average of $1.97 and a 200-day moving average of $2.09. The stock’s market capitalization is $33.86 million. Novogen has a one year low of $1.72 and a one year high of $3.09.

Novogen Company Profile

Novogen Limited (Novogen) is a drug discovery company. The Company is primarily engaged in pharmaceutical research and development. The Company’s operations include CanTx Inc, its United States-based joint venture company with Yale University. Novogen has two drug technology platforms (the superbenzopyrans (SBPs) and anti-tropomyosins (ATMs)) yielding drug candidates that have application across a range of degenerative diseases.

5 Day Chart for NASDAQ:NVGN

Get a free copy of the Zacks research report on Novogen (NVGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Novogen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novogen Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.